Soluble urokinase-type plasminogen activator receptor improves
early risk stratification in cardiogenic shock

J 2022

Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock

HONGISTO, Mari, Johan LASSUS, Tuukka TARVASMAKI, Jordi SANS-ROSELLO, Heli TOLPPANEN et. al.

Basic information

Original name

Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock

Authors

HONGISTO, Mari (guarantor), Johan LASSUS, Tuukka TARVASMAKI, Jordi SANS-ROSELLO, Heli TOLPPANEN, Anu KATAJA, Toni JANTTI, Tuija SABELL, Marek BANASZEWSKI, Jose SILVA-CARDOSO, John PARISSIS, Raija JURKKO, Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Maaret CASTREN, Alexandre MEBAZAA, Josep MASIP, Veli Pekka HARJOLA and CardShock Study Investigators And The Great NETWORK

Edition

EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, LONDON, SAGE PUBLICATIONS LTD, 2022, 2048-8726

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.100

RIV identification code

RIV/00216224:14110/22:00128426

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1093/ehjacc/zuac096

UT WoS

000838679300001

Keywords in English

Cardiogenic shock; suPAR; Risk stratification; Biomarker

Abstract

V originále

Aims Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker reflecting the level of immune activation. It has been shown to have prognostic value in acute coronary syndrome and heart failure as well as in critical illness. Considering the complex pathophysiology of cardiogenic shock (CS), we hypothesized suPAR might have prognostic properties in CS as well. The aim of this study was to assess the kinetics and prognostic utility of suPAR in CS. Methods and results SuPAR levels were determined in serial plasma samples (0-96 h) from 161 CS patients in the prospective, observational, multicentre CardShock study. Kinetics of suPAR, its association with 90-day mortality, and additional value in risk-stratification were investigated. The median suPAR-level at baseline was 4.4 [interquartile range (IQR) 3.2-6.6)] ng/mL. SuPAR levels above median were associated with underlying comorbidities, biomarkers reflecting renal and cardiac dysfunction, and higher 90-day mortality (49% vs. 31%; P = 0.02). Serial measurements showed that survivors had significantly lower suPAR levels at all time points compared with nonsurvivors. For risk stratification, suPAR at 12 h (suPAR(12h)) with a cut-off of 4.4 ng/mL was strongly associated with mortality independently of established risk factors in CS: OR 5.6 (95% CI 2.0-15.5); P = 0.001) for death by 90 days. Adding suPAR(12h) > 4.4 ng/mL to the CardShock risk score improved discrimination identifying high-risk patients originally categorized in the intermediate-risk category. Conclusion SuPAR associates with mortality and improves risk stratification independently of other previously known risk factors in CS patients.

Citovat

HONGISTO, Mari, Johan LASSUS, Tuukka TARVASMAKI, Jordi SANS-ROSELLO, Heli TOLPPANEN, Anu KATAJA, Toni JANTTI, Tuija SABELL, Marek BANASZEWSKI, Jose SILVA-CARDOSO, John PARISSIS, Raija JURKKO, Jindřich ŠPINAR, Maaret CASTREN, Alexandre MEBAZAA, Josep MASIP, Veli Pekka HARJOLA and CardShock Study Investigators And The Great NETWORK. Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock. EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE. LONDON: SAGE PUBLICATIONS LTD, 2022, vol. 11, No 10, p. 731-738. ISSN 2048-8726. Available from: https://dx.doi.org/10.1093/ehjacc/zuac096.

@article{2251370,
   author = {Hongisto, Mari and Lassus, Johan and Tarvasmaki, Tuukka and SansandRosello, Jordi and Tolppanen, Heli and Kataja, Anu and Jantti, Toni and Sabell, Tuija and Banaszewski, Marek and SilvaandCardoso, Jose and Parissis, John and Jurkko, Raija and Špinar, Jindřich and Castren, Maaret and Mebazaa, Alexandre and Masip, Josep and Harjola, Veli Pekka and Network, CardShock Study Investigators And The Great},
   article_location = {LONDON},
   article_number = {10},
   doi = {http://dx.doi.org/10.1093/ehjacc/zuac096},
   keywords = {Cardiogenic shock; suPAR; Risk stratification; Biomarker},
   language = {eng},
   issn = {2048-8726},
   journal = {EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE},
   title = {Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock},
   url = {https://academic.oup.com/ehjacc/article/11/10/731/6660742?login=true},
   volume = {11},
   year = {2022}
}

TY  - JOUR
ID  - 2251370
AU  - Hongisto, Mari - Lassus, Johan - Tarvasmaki, Tuukka - Sans-Rosello, Jordi - Tolppanen, Heli - Kataja, Anu - Jantti, Toni - Sabell, Tuija - Banaszewski, Marek - Silva-Cardoso, Jose - Parissis, John - Jurkko, Raija - Špinar, Jindřich - Castren, Maaret - Mebazaa, Alexandre - Masip, Josep - Harjola, Veli Pekka - Network, CardShock Study Investigators And The Great
PY  - 2022
TI  - Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock
JF  - EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
VL  - 11
IS  - 10
SP  - 731-738
EP  - 731-738
PB  - SAGE PUBLICATIONS LTD
SN  - 20488726
KW  - Cardiogenic shock
KW  - suPAR
KW  - Risk stratification
KW  - Biomarker
UR  - https://academic.oup.com/ehjacc/article/11/10/731/6660742?login=true
N2  - Aims Soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker reflecting the level of immune activation. It has been shown to have prognostic value in acute coronary syndrome and heart failure as well as in critical illness. Considering the complex pathophysiology of cardiogenic shock (CS), we hypothesized suPAR might have prognostic properties in CS as well. The aim of this study was to assess the kinetics and prognostic utility of suPAR in CS. Methods and results SuPAR levels were determined in serial plasma samples (0-96 h) from 161 CS patients in the prospective, observational, multicentre CardShock study. Kinetics of suPAR, its association with 90-day mortality, and additional value in risk-stratification were investigated. The median suPAR-level at baseline was 4.4 [interquartile range (IQR) 3.2-6.6)] ng/mL. SuPAR levels above median were associated with underlying comorbidities, biomarkers reflecting renal and cardiac dysfunction, and higher 90-day mortality (49% vs. 31%; P = 0.02). Serial measurements showed that survivors had significantly lower suPAR levels at all time points compared with nonsurvivors. For risk stratification, suPAR at 12 h (suPAR(12h)) with a cut-off of 4.4 ng/mL was strongly associated with mortality independently of established risk factors in CS: OR 5.6 (95% CI 2.0-15.5); P = 0.001) for death by 90 days. Adding suPAR(12h) > 4.4 ng/mL to the CardShock risk score improved discrimination identifying high-risk patients originally categorized in the intermediate-risk category. Conclusion SuPAR associates with mortality and improves risk stratification independently of other previously known risk factors in CS patients.
ER  -

HONGISTO, Mari, Johan LASSUS, Tuukka TARVASMAKI, Jordi SANS-ROSELLO, Heli TOLPPANEN, Anu KATAJA, Toni JANTTI, Tuija SABELL, Marek BANASZEWSKI, Jose SILVA-CARDOSO, John PARISSIS, Raija JURKKO, Jindřich ŠPINAR, Maaret CASTREN, Alexandre MEBAZAA, Josep MASIP, Veli Pekka HARJOLA and CardShock Study Investigators And The Great NETWORK. Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock. \textit{EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE}. LONDON: SAGE PUBLICATIONS LTD, 2022, vol.~11, No~10, p.~731-738. ISSN~2048-8726. Available from: https://dx.doi.org/10.1093/ehjacc/zuac096.

Detailed Information on Publication Record